PEGylated helper-dependent adenoviral vectors: Highly efficient vectors wih an enhanced safety profile

Gene Therapy

Volumn 12, Issue 7, 2005, Pages 579-587

  Croyle, M A ^a   Le, H T ^a   Linse, K D ^a   Cerullo, V ^b,c   Toietta, G ^d   Beaudet, A ^d   Pastore, L ^b,c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Helper dependent adenoviral vectors; Immune response; PEGylation; Readministration; Toxicology

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ALPHA 1 ANTITRYPSIN; ASPARTATE AMINOTRANSFERASE; BETA GALACTOSIDASE; INTERLEUKIN 12; INTERLEUKIN 6; MACROGOL; SUCCINIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONJUGATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSDUCTION; HELPER CELL; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; LIVER HOMOGENATE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROVOCATION TEST; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TOXICITY TESTING; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE;

ADENOVIRIDAE; ANIMALS; BETA-GALACTOSIDASE; CHEMISTRY, PHYSICAL; CYTOKINES; DRUG CARRIERS; GENE EXPRESSION; GENETIC VECTORS; LIVER; MALE; MICE; MICE, INBRED C57BL; PLATELET COUNT; POLYETHYLENE GLYCOLS; SURFACE PROPERTIES; TRANSAMINASES; TRANSDUCTION, GENETIC;

MIRIDAE;

EID: 16344373567     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302441     Document Type: Article

References (46)

1. Ginsberg HS. The life and times of adenoviruses. Adv Virus Res 1999; 54: 1-13.
2. Jaffe HA et al. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet 1992; 1 372-378.
3. Gomez-Foix AM et al. Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism. J Biol Chem 1992; 267: 25129-25134.
4. Nunes FA, Furth EE, Wilson JM, Raper SE. Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Hum Gene Ther 1999; 10: 2515-2526.
5. Christ M et al. Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products. Hum Gene Ther 2000; 11: 415-427.
6. Pastore L et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther 1999; 10: 1773-1781.
7. Morral N et al. Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum Gene Ther 2002; 13: 143-154.
8. Muruve DA, Barnes MJ, Stillman IE, Libermann TA. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 1999; 10: 965-976.
9. Lieber A et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 1997; 71: 8798-8807.
10. Zhang Y et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 2001; 3: 697-707.
11. Liu Q, Muruve DA. Molecular basis of the inflammatory response to adenovirus vectors. Gene Therapy 2003; 10: 935-940.
12. Jooss K, Ertl HC, Wilson JM. Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J Virol 1998; 72: 2945-2954.
13. Yang Y et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adeno-virus-infected adenovirus hepatocytes in vivo. Gene Therapy 1996; 3: 137-144.
14. Yang Y, Wilson JM. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLAs in vivo. J Immunol 1995; 155: 2564-2570.
15. Raper SE et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-158.
16. Schnell MA et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 2001; 3: 708-722.
17. Yang Y, Greenough K, Wilson JM. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Therapy 1996; 3: 412-420.
18. Kochanek S, Schiedner G, Volpers C. High-capacity 'gutless' adenoviral vectors. Curr Opin Mol Ther 2001; 3: 454-463.
19. O'Neal WK et al. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. Mol Med 2000; 6: 179-195.
20. Morral N et al. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Hum Gene Ther 1998; 9: 2709-2716.
21. Kim IH et al. Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA 2001; 98: 13282-13287.
22. Oka K et al. Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. Circulation 2001; 103: 1274-1281.
23. Schiedner G et al. Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors. Mol Ther 2003; 7: 35-43.
24. Brunetti-Pierri N et al. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 2004; 15: 35-46.
25. Muruve DA et al. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol 2004; 78: 5966-5972.
26. Parks RJ, Evelegh CM, Graham FL. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Therapy 1999; 6: 1565-1573.
27. Croyle MA, Chirmule N, Zhang Y, Wilson JM. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther 2002; 13: 1887-1900.
28. Croyle MA, Yu QC, Wilson JM. Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum Gene Ther 2000; 11: 1721-1730.
29. Sims GEC, Snape TJ. A method for the estimation of polyethylene glycol in plasma protein fractions. Anal Biochem 1980; 107: 60-63.
30. Liu Q et al. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther 2003; 14: 627-643.
31. Trapnell BC, Shanley TP. Innate immune response to in vivo adenovirus infection. In: Curiel D, Douglas JT (eds). Adenoviral Vectors for Gene Therapy. Academic Press: San Diego, 2002, pp 349-373.
32. Quimby FW. The Mouse. In: Loeb WF, Quimby FW (eds). The Clinical Chemistry of Laboratory Animals. Taylor and Francis: Philadelphia, 1999, pp 3-33.
33. Saito T et al. Immune tolerance induced by polyethylene glycol-conjugate of protein antigen: clonal deletion of antigen-specific Th-cells in the thymus. J Biomater Sci Polym Ed 2000; 11: 647-656.
34. So T et al. Extended blood half-life of monomethoxypolyethylene glycol-conjugated hen lysozyme is a key parameter controlling immunological tolerogenicity. Cell Mol Life Sci 1999; 55: 1187-1194.
35. Harris JM, Chess RB. Effect of PEGylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2: 214-221.
36. Terregino CA et al. Endogenous mediators in emergency department patients with presumed sepsis: are levels associated with progression to severe sepsis and death? Ann Emerg Med 2000; 35 26-34.
37. Wolins N et al. Intravenous administration of replication-incompetent adenovirus to rhesus monkeys induces thrombocytopenia by increasing in vivo platelet clearance. Br J Hematol 2003; 123: 903-905.
38. Zucker-Franklin D. Platelets in viral infection. In: Joseph M (ed). Immunopharmacology of Platelets. Elsevier Science & Technology: London, 1995, pp 137-151.
39. Davis FF. The origin of pegnology. Adv Drug Deliv Rev 2002; 54: 457-458.
40. Working PK, Newman MS, Johnson J, Cornacoff JB. Safety of poly(ethylene glycol) and poly(ethylene glycol) derivatives. In: Harris JM, Zalipsky S (eds). Poly(ethylene glycol) Chemistry and Biological Applications. American Chemical Society: Washington, DC, 1997, pp 45-57.
41. Zou L, Zhou H, Pastore L, Yang K. Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system. Mol Ther 2000; 2: 105-113.
42. Schiedner G et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18: 180-183.
43. Parks RJ et al. A helper-dependent adenovirus vector system: removal of helper virus by cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996; 93: 13565-13570.
44. Zhou H, Pastore L, Beaudet AL. Helper-dependent adenoviral vectors. Meth Enzymol 2002; 346: 177-198.
45. Maizel Jr JV, White DO, Scharff MD. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 1968; 36: 115-125.
46. O'Riordan C et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 1999; 10: 1349-1358.